# Plasma Protease C1 Inhibitor Market

> Plasma Protease C1 Inhibitor Market Research Report: Size, Share, Trend Analysis By Product Formulation (Liquid Formulation, Lyophilized Formulation, Recombinant Formulation), By Indication (Hereditary Angioedema, Acquired Angioedema, Other Complement Disorders), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End Users (Hospitals, Clinics, Homecare Settings), By Administration Route (Intravenous, Subcutaneous) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.47%
- **2024:** $ 1.11 Billion
- **2025:** $ 1.16 Billion
- **2035:** $ 1.79 Billion
- **Key Players:** Shire (GB), CSL Behring (AU), Grifols(ES), Octapharma (CH), Takeda (JP), Baxter (US), LFB (FR), Sobi (SE)

**Report ID:** MRFR/HC/30661-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/plasma-protease-c1-inhibitor-market-32457

---

## Market Summary

## **Plasma Protease C1 Inhibitor Market Overview**

As per MRFR analysis, the Plasma Protease C1 Inhibitor Market Size was estimated at 1.11 (USD Billion) in 2024. The Plasma Protease C1 Inhibitor Market Industry is expected to grow from 1.16 (USD Billion) in 2025 to 1.71 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.47% during the forecast period (2025 - 2034).

### **Key Plasma Protease C1 Inhibitor Market Trends Highlighted**

The Plasma Protease C1 Inhibitor Market is experiencing significant growth driven by an increase in the prevalence of rare diseases such as hereditary angioedema, which necessitates effective therapeutic interventions. The rising awareness regarding these conditions and advancements in biotechnology have led to enhanced product offerings that target specific patient needs.

Additionally, the ongoing research and development activities aimed at improving the efficacy and safety profile of C1 inhibitors have spurred market momentum. Regulatory approvals and supportive healthcare policies further contribute to market expansion by facilitating easier access to these treatments for patients in need.

Opportunities exist for market participants to explore and capture unmet needs within the sector, particularly in emerging markets where healthcare infrastructure is developing rapidly. Collaborations between pharmaceutical companies and research institutions could lead to innovative therapies, tapping into niche segments that remain underserved. Furthermore, the growing trend of personalized medicine is gaining traction, presenting avenues for tailored treatment options that resonate better with patients’ unique biological profiles, thereby enhancing patient adherence and outcomes.

Recent trends in the Plasma Protease C1 Inhibitor Market include increasing investment in technologies that enhance the manufacturing process of these inhibitors and the emergence of novel delivery systems that improve patient experience. Telemedicine and digital health solutions are also gaining prominence, facilitating better patient management and monitoring.

The shift towards preventive measures and education initiatives aimed at patients and healthcare providers reflects a broader understanding of the disease landscape, ensuring that patients receive timely and effective care. Overall, these dynamic components are shaping the future of the market, aligning with the evolving healthcare ecosystem.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Plasma Protease C1 Inhibitor Market Drivers**

### **Increasing Prevalence of Hereditary Angioedema**

The rising incidence of hereditary angioedema (HAE) significantly propels the growth of the Plasma Protease C1 Inhibitor Market Industry. HAE is a genetic disorder that causes episodes of severe swelling in various parts of the body, including the hands, feet, gut, and airways.

The lack of effective treatments in the past has led to a heightened focus on developing and commercializing plasma protease C1 inhibitors, as these have shown efficacy in managing HAE symptoms.As the awareness of hereditary angioedema increases among healthcare professionals and patients, the demand for plasma protease C1 inhibitors rises.

In addition, the effective management of HAE symptoms through innovative treatments has become a priority for many healthcare systems, further boosting the market. 

Additionally, advancements in genetic testing and the increasing number of diagnosed cases are expected to create a larger patient population that requires treatment, consequently driving market revenue.As medical professionals rely on novel therapies to reduce the frequency and severity of angioedema attacks, the Plasma Protease C1 Inhibitor Market Industry is experiencing robust growth. Moreover, healthcare funding and support for research to enhance the understanding of HAE will likely contribute to the market's expansion in the coming years.

### **Growing Investment in Research and Development**

Investment in research and development (R) activities is a critical driver for the Plasma Protease C1 Inhibitor Market Industry. With more pharmaceutical companies focusing on innovating and improving therapeutic options for patients suffering from conditions such as hereditary angioedema, increased resources are being allocated toward the discovery of new molecules and formulations.

As a result, the pipeline for plasma protease C1 inhibitors is becoming more robust, ensuring a steady influx of advanced treatment options to meet the growing patient demand.Furthermore, partnerships and collaborations between organizations to develop novel therapeutic solutions are expected to enhance product offerings and availability, thus stimulating market growth.

### **Rising Awareness and Acceptance of Biologic Therapies**

The increasing awareness and acceptance of biological therapies within the medical community and among patients is driving the growth of the Plasma Protease C1 Inhibitor Market Industry. As healthcare professionals become more knowledgeable about the benefits and effectiveness of biologic treatments, patients are more likely to seek out these advanced options for managing their conditions.

The shift towards biologics is also supported by various initiatives aimed at educating healthcare providers and patients alike on the advantages of using plasma protease C1 inhibitors for conditions such as hereditary angioedema.As the acceptance of such therapies grows, the market potential for plasma protease C1 inhibitors expands, leading to greater investments and development in this industry.

## **Plasma Protease C1 Inhibitor Market Segment Insights**

### **Plasma Protease C1 Inhibitor Market Product Formulation Insights**

The Plasma Protease C1 Inhibitor Market, particularly in the Product Formulation segment, demonstrates a clear path of growth and significant future valuations. With the market valued at 1.01 USD Billion in 2023, it is expected to reach a notable 1.5 USD Billion by 2032, showcasing robust market growth driven by increased incidence of disorders related to complement deficiencies and rising awareness towards treatment therapies.

Among the formulations, Liquid Formulation holds a majority share, with a valuation of 0.45 USD Billion in 2023, rising to 0.66 USD Billion by 2032.This formulation is favored due to its ease of administration and quicker patient response times, making it a vital option in therapeutic applications. 

Lyophilized Formulation follows closely with a strength of 0.35 USD Billion in 2023, expanding to 0.51 USD Billion by 2032, recognized for its longer shelf-life and stability, which is crucial in situations requiring long-term storage and transport of medications. Recombinant Formulation, while currently the smallest segment at a valuation of 0.21 USD Billion in 2023, with projections of reaching 0.32 USD Billion by 2032, is gaining traction due to advancements in biotechnology and the critical need for more tailored therapies.

The steady growth of this segment is fueled by increasing research and development efforts aimed at harnessing recombinant technologies for better patient outcomes. Overall, the Plasma Protease C1 Inhibitor Market segmentation reflects not only market dynamics but also ongoing innovations and regulatory advancements, creating unique opportunities in the industry that are worthy of exploration.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Plasma Protease C1 Inhibitor Market Indication Insights**

The Plasma Protease C1 Inhibitor Market is projected to reach a valuation of 1.01 billion USD by 2023, reflecting steady growth driven by diverse indication categories. Among these, Hereditary Angioedema has gained prominence due to its genetic predisposition and the critical need for effective treatment strategies.

Acquired Angioedema is also significant, as it arises from various underlying conditions, posing unique treatment challenges. Other Complement Disorders, while less highlighted, further contribute to the market landscape, showcasing the extensive need for therapeutic interventions across various indications.

Together, these segments represent a substantial portion of the market, emphasizing the importance of targeted therapies and robust research efforts in improving patient outcomes. The Plasma Protease C1 Inhibitor Market segmentation allows for a more nuanced understanding of treatment needs, driving innovation and development in this area of the industry while addressing market growth opportunities.

As the market expands, the focus on effective management of these conditions remains a priority, reflecting the evolving healthcare landscape and the demand for comprehensive care solutions.

### **Plasma Protease C1 Inhibitor Market Distribution Channel Insights**

The Plasma Protease C1 Inhibitor Market exhibits a well-structured distribution channel, encompassing Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. In 2023, the overall market achieved a valuation of 1.01 billion USD, showcasing a robust framework for delivering these essential products to customers.

Hospital Pharmacies play a crucial role, particularly due to their proximity to healthcare providers, thereby facilitating prompt access to required medications for patients. Retail Pharmacies contribute significantly by catering to a broad consumer base, ensuring the availability of plasma protease C1 inhibitors outside hospital settings.

Meanwhile, Online Pharmacies have emerged as an increasingly vital channel, capitalizing on the growing trend of e-commerce in pharmaceutical sales, providing convenience and accessibility to users. The segmentation within the Plasma Protease C1 Inhibitor Market illustrates varied dynamics, but the collective strength of these distribution channels is pivotal in meeting the needs of patients and healthcare providers alike, driving market growth and facilitating broader access to critical treatments.

### **Plasma Protease C1 Inhibitor Market End User Insights   **

The Plasma Protease C1 Inhibitor Market revenue is shaped significantly by its End User segment, which includes various healthcare settings like hospitals, clinics, and home care. In 2023, the market is projected to be valued at 1.01 USD Billion, with a steady growth trend expected. Hospitals play a crucial role in the distribution of plasma protease C1 inhibitors due to their capacity to manage complex cases of conditions like hereditary angioedema. Clinics also contribute to the market by offering specialized treatments and consultations, serving as vital points of care for patients.

Homecare settings are increasingly important, reflecting a shift towards patient-centered care that allows individuals to receive treatment in a comfortable environment. This segment is expected to gain traction as more people prefer at-home services, enhancing accessibility and convenience. The Plasma Protease C1 Inhibitor Market segmentation underlines the evolving landscape of healthcare delivery, where each setting addresses unique patient needs and preferences, driving the overall market growth.

### **Plasma Protease C1 Inhibitor Market Administration Route Insights   **

The Plasma Protease C1 Inhibitor Market is poised for notable growth, with a significant valuation of 1.01 USD Billion expected in 2023. The Administration Route segment plays a crucial role in this market, characterized by various methods of delivery that enhance patient accessibility and treatment efficacy. Among these, intravenous and subcutaneous routes are particularly noteworthy. The intravenous route is often favored in clinical settings due to its rapid onset of action and direct bioavailability, thus providing immediate therapeutic effects.

Conversely, the subcutaneous route offers an advantage in patient convenience, allowing for self-administration and reducing the need for hospital visits. This flexibility has led to increased acceptance, particularly among patients desiring more autonomy in their treatment regimens.

Overall, the growing demand for innovative treatment options and the increasing prevalence of related health conditions are driving the expansion of the Plasma Protease C1 Inhibitor Market, with both administration routes contributing significantly to its progression and dynamics in the industry.

### **Plasma Protease C1 Inhibitor Market Regional Insights   **

The Regional segment of the Plasma Protease C1 Inhibitor Market has shown dynamic growth, with North America being the majority holding sector at a valuation of 0.51 USD Billion in 2023, expected to rise to 0.7 USD Billion by 2032. Europe follows closely, significantly contributing with a valuation of 0.3 USD Billion in 2023 and projected to reach 0.44 USD Billion in 2032, indicating robust demand.

The Asia Pacific region, valued at 0.15 USD Billion in 2023, is gaining traction due to increasing healthcare investments, with expectations reaching 0.21 USD Billion by 2032.Meanwhile, the Middle East and Africa, along with South America, represent smaller segments of the market, valued at 0.02 USD Billion and 0.03 USD Billion, respectively, in 2023. 

While these regions have lower valuations currently, they hold potential for future growth due to expanding awareness and healthcare access. Overall, the Plasma Protease C1 Inhibitor Market segmentation reflects varying regional demands influenced by healthcare infrastructure, regulatory changes, and the growing prevalence of related health conditions, contributing to market growth in all areas.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Plasma Protease C1 Inhibitor Market Key Players And Competitive Insights**

The Plasma Protease C1 Inhibitor Market has evolved significantly in recent years, driven by the increasing prevalence of hereditary angioedema and the growing awareness of the importance of C1 inhibitor replacement therapy. Competitive insights in this market encompass the major players, their product portfolios, market strategies, and regional presence.

With advancements in biotechnology and the constant demand for effective treatment options, firms are focusing on not only product innovation but also collaborations and strategic partnerships to enhance their competitive edge. The market is characterized by stringent regulatory frameworks that necessitate continuous investment in research and development, influencing how companies position themselves and their offerings. 

The competitive landscape is further shaped by emerging companies that aim to challenge established players, indicating a dynamic environment.Octapharma has established a strong market presence within the Plasma Protease C1 Inhibitor Market, capitalizing on its extensive expertise in plasma-derived products. With a robust focus on improving patient outcomes, Octapharma primarily concentrates its efforts on innovation and quality assurance, ensuring that its C1 inhibitor therapies meet the highest standards.

The company leverages its global reach to cater to diverse markets, strengthening its distribution networks and solidifying customer relationships. Its commitment to research and development enables Octapharma to stay at the forefront of therapeutic advancements, offering a comprehensive range of product applications that cater to the varying needs of different patient demographics. 

The organization’s ability to maintain a strong supply chain enhances its competitive positioning, allowing it to effectively respond to market demands as they arise.Bio Products Laboratory is also a significant contender in the Plasma Protease C1 Inhibitor Market, illustrating its commitment to providing high-quality plasma-derived therapies.

The company recognizes the importance of developing C1 inhibitors tailored for patients with hereditary angioedema, and its product range is distinguished by rigorous quality control measures and clinical efficacy. Bio Products Laboratory places a strong emphasis on sustainability and ethical sourcing in its manufacturing processes, appealing to an increasingly conscious consumer base.

The firm prioritizes partnerships with healthcare providers and advocacy groups, enhancing its understanding of patient needs and contributing to more effective treatment options. Through ongoing investment in innovation and a patient-centric approach, Bio Products Laboratory seeks to expand its role while navigating the competitive landscape with strategic foresight.

## **Key Companies in the Plasma Protease C1 Inhibitor Market Include**

- Octapharma
- Bio Products Laboratory
- Sobi
- CSL Behring
- LFB Group
- HoffmannLa Roche
- Hairec Pharma
- Grifols
- Emergent BioSolutions
- **[ADMA Biologics](https://ir.admabiologics.com/static-files/cbf5cee3-9e78-4fe7-8092-536b565c2078)**
- ProMetic Life Sciences
- Takeda Pharmaceutical Company
- Baxter International
- Cangene Corporation

## Plasma Protease C1 Inhibitor Market Industry Developments

- **Q1 2024: Takeda Receives FDA Approval for TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe for Hereditary Angioedema** Takeda announced that the U.S. FDA approved a new prefilled syringe presentation of TAKHZYRO® (lanadelumab-flyo) for the prevention of hereditary angioedema attacks, expanding administration options for patients.
- **Q2 2024: CSL Behring Opens New Plasma Fractionation Facility in Marburg, Germany** CSL Behring inaugurated a new plasma fractionation facility in Marburg to increase production capacity for plasma-derived therapies, including C1-inhibitor products.
- **Q2 2024: Pharming Group Announces FDA Acceptance of sBLA for RUCONEST® for Expanded Indication** Pharming Group reported that the U.S. FDA accepted its supplemental Biologics License Application (sBLA) for RUCONEST® (C1 esterase inhibitor [recombinant]) to expand its indication for hereditary angioedema.
- **Q3 2024: Takeda Announces Partnership with BioLife Plasma Services to Expand Plasma Collection for C1-Inhibitor Therapies** Takeda entered a partnership with BioLife Plasma Services to increase plasma collection capacity, supporting the production of plasma-derived C1-inhibitor therapies.
- **Q3 2024: CSL Behring Receives European Commission Approval for Berinert® for Pediatric Use** CSL Behring received European Commission approval to extend the use of Berinert® (C1 esterase inhibitor) to pediatric patients with hereditary angioedema.
- **Q4 2024: Pharming Group Appoints New Chief Medical Officer** Pharming Group announced the appointment of a new Chief Medical Officer to oversee clinical development of its C1-inhibitor portfolio.
- **Q1 2025: Takeda Launches TAKHZYRO® Prefilled Syringe in Europe** Takeda launched the prefilled syringe formulation of TAKHZYRO® (lanadelumab-flyo) in several European countries, expanding access to hereditary angioedema patients.
- **Q1 2025: CSL Behring Announces Expansion of Kankakee Manufacturing Facility** CSL Behring announced a major expansion of its Kankakee, Illinois manufacturing facility to increase production of plasma-derived therapies, including C1-inhibitor products.
- **Q2 2025: Pharming Group Receives FDA Approval for Expanded RUCONEST® Indication** Pharming Group received FDA approval for an expanded indication of RUCONEST® (C1 esterase inhibitor [recombinant]) for the treatment of hereditary angioedema in additional patient populations.
- **Q2 2025: Takeda Announces New Plasma Collection Center Opening in Texas** Takeda opened a new plasma collection center in Texas to support the growing demand for plasma-derived C1-inhibitor therapies.

## **Plasma Protease C1 Inhibitor Market Segmentation Insights**

### **Plasma Protease C1 Inhibitor Market Product Formulation Outlook**

- Liquid Formulation
- Lyophilized Formulation
- Recombinant Formulation

### **Plasma Protease C1 Inhibitor Market Indication Outlook**

- Hereditary Angioedema
- Acquired Angioedema
- Other Complement Disorders

### **Plasma Protease C1 Inhibitor Market Distribution Channel Outlook**

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

### **Plasma Protease C1 Inhibitor Market End User Outlook**

- Hospitals
- Clinics
- Homecare Settings

### **Plasma Protease C1 Inhibitor Market Administration Route Outlook**

- Intravenous
- Subcutaneous

### **Plasma Protease C1 Inhibitor Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Awareness and Education Initiatives

The increasing awareness and education initiatives surrounding hereditary angioedema are driving growth in the Plasma Protease C1 Inhibitor Market. Healthcare providers, patients, and advocacy groups are actively working to disseminate information about HAE, its symptoms, and available treatment options. This heightened awareness is leading to earlier diagnosis and treatment, which is crucial for managing the condition effectively. As more patients seek treatment, the demand for plasma protease C1 inhibitors is likely to rise. Additionally, educational programs aimed at healthcare professionals are improving the understanding of HAE, further contributing to the market's expansion as more practitioners become equipped to manage this rare disease.

### Growing Prevalence of Hereditary Angioedema

The rising incidence of hereditary angioedema (HAE) is a primary driver for the Plasma Protease C1 Inhibitor Market. HAE is a genetic condition characterized by recurrent episodes of severe swelling, which can be life-threatening. As awareness of this condition increases, more patients are being diagnosed and treated. Recent estimates suggest that the prevalence of HAE is approximately 1 in 50,000 individuals, leading to a growing patient population in need of effective therapies. This surge in demand for plasma protease C1 inhibitors, which are critical in managing HAE, is likely to propel market growth. Furthermore, the increasing number of healthcare professionals specializing in rare diseases contributes to the identification and treatment of HAE, thereby expanding the market for plasma protease C1 inhibitors.

### Regulatory Support for Innovative Therapies

Regulatory bodies are increasingly providing support for the development and approval of innovative therapies in the Plasma Protease C1 Inhibitor Market. Initiatives such as orphan drug designations and expedited review processes are encouraging pharmaceutical companies to invest in the development of new treatments for rare diseases like HAE. This regulatory environment fosters innovation and accelerates the availability of new therapies to patients in need. As a result, the market is likely to see a rise in the number of approved plasma protease C1 inhibitors, which will enhance treatment options for patients and drive overall market growth. The supportive regulatory landscape is a crucial factor in shaping the future of the plasma protease C1 inhibitor market.

### Increasing Investment in Rare Disease Research

The growing investment in research and development for rare diseases is a significant driver for the Plasma Protease C1 Inhibitor Market. Governments and private organizations are increasingly allocating funds to support research initiatives aimed at understanding and treating rare conditions such as HAE. This trend is reflected in the rising number of clinical trials and studies focused on plasma protease C1 inhibitors. In recent years, the number of clinical trials for HAE treatments has increased, indicating a robust pipeline of potential therapies. This influx of investment not only fosters innovation but also enhances the likelihood of new product approvals, thereby expanding the market for plasma protease C1 inhibitors.

### Technological Advancements in Drug Development

Technological innovations in drug development are significantly influencing the Plasma Protease C1 Inhibitor Market. Advances in biotechnology, such as recombinant DNA technology and monoclonal antibody production, have enhanced the efficacy and safety profiles of plasma protease C1 inhibitors. These innovations allow for the development of more targeted therapies, which are increasingly preferred by healthcare providers and patients alike. The market has witnessed a shift towards biologics, with a notable increase in the approval of new therapies that utilize these advanced technologies. As a result, the market is expected to expand, driven by the introduction of novel products that offer improved outcomes for patients suffering from conditions like HAE.

## Future Outlook

The Plasma Protease C1 Inhibitor Market is projected to grow at a 4.47% CAGR from 2025 to 2035, driven by increasing prevalence of hereditary angioedema and advancements in therapeutic technologies.

**New opportunities:**

- Expansion of telehealth services for remote patient monitoring Development of combination therapies to enhance treatment efficacy Investment in personalized medicine approaches for targeted therapies

By 2035, the market is expected to achieve robust growth, positioning itself as a leader in innovative therapeutic solutions.

## Segment Insights

### By Product Formulation: Liquid Formulation (Largest) vs. Lyophilized Formulation (Fastest-Growing)

In the Plasma Protease C1 Inhibitor Market, the distribution of market share among product formulations shows that Liquid Formulation holds the largest segment. This formulation type benefits from its ease of use and immediate efficacy, making it a preferred choice for many clinicians and patients alike. On the other hand, Lyophilized Formulation, although smaller in market share, is emerging rapidly due to its stability and convenient storage, appealing to both manufacturers and consumers looking for long-term solutions.

Liquid Formulation (Dominant) vs. Lyophilized Formulation (Emerging)

Liquid Formulation, known for its ready-to-use characteristics, dominates the Plasma Protease C1 Inhibitor Market thanks to its rapid onset of action in clinical settings. This formulation allows for immediate therapeutic intervention, making it highly favored among patients requiring urgent care. In contrast, Lyophilized Formulation is gaining traction as an emerging option; its shelf-stable nature makes it particularly attractive in regions where refrigeration is a challenge. The growth of this segment is driven by the increasing focus on patient convenience and the need for efficient supply chains, positioning it as a vital player in the evolving landscape of plasma therapies.

### By Indication: Hereditary Angioedema (Largest) vs. Acquired Angioedema (Fastest-Growing)

The Plasma Protease C1 Inhibitor Market is significantly influenced by the indications for treatment, with Hereditary Angioedema (HAE) commanding the largest market share due to its prevalence and the rising awareness of treatment options. Acquired Angioedema, while having a smaller market share, is rapidly gaining attention, reflecting a shift in focus among healthcare providers and the introduction of innovative therapies specifically targeting this condition. Other Complement Disorders remain a niche segment, contributing to market diversity.

Hereditary Angioedema (Dominant) vs. Acquired Angioedema (Emerging)

Hereditary Angioedema is characterized by recurrent episodes of swelling and is typically managed with plasma-derived C1 inhibitors, making it the dominant indication in this market. This condition has an established treatment landscape, fostering familiarity among practitioners and patients alike. Conversely, Acquired Angioedema is emerging as a critical indication, driven by increasing diagnoses and tailored therapies entering the market. Its growth is bolstered by improvements in clinical guidelines and heightened awareness, suggesting that investment in this area may yield significant advancements in patient care and outcomes.

### By Distribution Channel: Hospital Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

In the Plasma Protease C1 Inhibitor Market, Hospital Pharmacies hold the largest market share among distribution channels. They serve as a critical point for patients requiring specialized care, providing direct access to these essential medications. Meanwhile, Retail Pharmacies play a significant role, offering convenience and accessibility, but they are outpaced by the growth of online alternatives. Online Pharmacies are emerging rapidly as a viable distribution channel due to the increasing consumer preference for online shopping and the convenience it brings. The growth in telehealth services and remote patient management is further driving this trend. As digital platforms continue to expand, Online Pharmacies are expected to capture more market share, providing therapeutic options directly to consumers with enhanced ease.

Hospital Pharmacies (Dominant) vs. Online Pharmacies (Emerging)

Hospital Pharmacies are at the forefront of the Plasma Protease C1 Inhibitor Market, due to their established infrastructure, direct connection to healthcare professionals, and the critical role they play in patient care. They ensure a steady supply of these specialized treatments, often working closely with hospitals to manage patient therapy effectively. In contrast, Online Pharmacies represent an emerging segment, driven by the increasing demand for accessibility and convenience. They cater to a tech-savvy consumer base that prefers ordering medications from home. As regulations evolve to support online sales, these pharmacies are likely to expand significantly, creating more competition in the market.

### By End User: Hospitals (Largest) vs. Homecare Settings (Fastest-Growing)

In the Plasma Protease C1 Inhibitor Market, hospitals account for the largest share, serving as primary treatment centers for patients requiring these therapies. This segment benefits from established infrastructure and comprehensive medical services that promote the effective use of plasma protease C1 inhibitors. Clinics and homecare settings follow, providing essential health services but capturing a smaller market share compared to hospitals. As healthcare delivery models evolve, this distribution may see shifts as demand changes in various care environments. Growth trends in this segment are increasingly influenced by patient preferences for receiving treatment in more convenient settings, such as homecare. Advances in technology and the development of patient-friendly formulations support this trend. Additionally, as healthcare systems strive to reduce costs and improve patient outcomes, homecare settings are becoming a focal point for treatment, indicating a dynamic shift in the market landscape.

Hospitals: Dominant vs. Homecare Settings: Emerging

In the Plasma Protease C1 Inhibitor Market, hospitals have established their position as the dominant end-user segment. They provide comprehensive clinical facilities and specialist healthcare teams, making them essential for the administration of complex therapies like plasma protease C1 inhibitors. The availability of resources and skilled personnel supports optimal treatment protocols in hospital settings. Conversely, homecare settings are fast emerging as a vital segment due to their ability to offer convenient and personalized care. This segment appeals to patients seeking flexibility in their treatment options, particularly for chronic conditions requiring ongoing management. Continuous innovations in homecare technology and supportive services are paving the way for growth and expanded acceptance of these therapies outside traditional hospital environments.

### By Administration Route: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

In the Plasma Protease C1 Inhibitor Market, the distribution of market share between intravenous and subcutaneous administration routes reveals a strong preference for intravenous methods. This route dominates the market due to its quick absorption rates and established efficacy in delivering treatment to patients with hereditary angioedema. The intravenous administration segment accounts for a considerable percentage of the market, attributed to its long-standing presence and acceptance among healthcare professionals.

Administration Route: Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration of plasma protease C1 inhibitors is the dominant route of delivery, widely recognized for its effectiveness in treating acute episodes of angioedema. This method allows for direct delivery into the bloodstream, ensuring rapid therapeutic action which is critical in emergency scenarios. Conversely, the subcutaneous route is emerging rapidly, favored for its ease of use and convenience in outpatient settings. This method offers patients a self-administration option, improving adherence and reducing the need for frequent hospital visits. The increasing demand for home-based treatments and favorable patient experiences are driving the subcutaneous segment's growth, reflecting a significant trend towards more patient-centric care in the market.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is the largest market for Plasma Protease C1 Inhibitor Market, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of hereditary angioedema, and strong regulatory support. The demand is further driven by increasing awareness and the availability of innovative therapies. Regulatory bodies like the FDA play a crucial role in expediting approvals, enhancing market growth. The United States is the leading country in this market, followed by Canada. Major players such as Shire, Baxter, and CSL Behring have a significant presence, contributing to a competitive landscape. The focus on research and development, along with strategic partnerships, is expected to bolster market growth. The presence of established healthcare systems and reimbursement policies also supports the adoption of these therapies.

### Europe : Emerging Market Dynamics

Europe is witnessing significant growth in the Plasma Protease C1 Inhibitor Market, accounting for approximately 30% of the global share. The region benefits from a robust healthcare system, increasing patient population, and favorable reimbursement policies. Regulatory frameworks, such as those from the European Medicines Agency (EMA), are pivotal in facilitating market entry for new therapies, thus driving demand. Leading countries in this region include Germany, France, and the UK, where the presence of key players like Grifols and Octapharma is notable. The competitive landscape is characterized by a mix of established companies and emerging biotech firms. Collaborative efforts in research and development are enhancing product offerings, while increasing awareness of hereditary angioedema is further propelling market growth.

### Asia-Pacific : Rapidly Growing Market Potential

The Asia-Pacific region is emerging as a significant player in the Plasma Protease C1 Inhibitor Market, holding about 20% of the global market share. Factors such as rising healthcare expenditure, increasing awareness of rare diseases, and improving healthcare infrastructure are driving this growth. Countries like Japan and Australia are leading the market, supported by favorable regulatory environments that encourage innovation and accessibility to treatments. Japan is the largest market in this region, followed by Australia and China. The competitive landscape features both local and international players, including Takeda and CSL Behring. The focus on expanding distribution networks and enhancing patient access to therapies is crucial for market growth. Additionally, collaborations between pharmaceutical companies and healthcare providers are expected to foster innovation and improve treatment outcomes.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa (MEA) region represents an untapped market for Plasma Protease C1 Inhibitor Market, holding approximately 5% of the global market share. The growth is driven by increasing healthcare investments, rising awareness of rare diseases, and the need for advanced treatment options. Regulatory bodies are beginning to establish frameworks that support the introduction of innovative therapies, which is expected to catalyze market growth in the coming years. Countries like South Africa and the UAE are at the forefront of this market, with a growing number of healthcare facilities and increasing patient populations. The competitive landscape is still developing, with opportunities for both local and international players to enter the market. Partnerships with healthcare providers and government initiatives aimed at improving healthcare access are essential for driving growth in this region.

## Competitive Benchmarking

The Plasma Protease C1 Inhibitor Market is characterized by a dynamic competitive landscape, driven by increasing awareness of hereditary angioedema (HAE) and the growing demand for effective treatment options. Key players such as Shire (GB), CSL Behring (AU), and Grifols (ES) are strategically positioned to leverage their extensive product portfolios and innovative capabilities. Shire (GB) focuses on enhancing its therapeutic offerings through continuous research and development, while CSL Behring (AU) emphasizes The Plasma Protease C1 Inhibitor Market presence. Grifols (ES) appears to be concentrating on technological advancements in manufacturing processes, which may bolster its competitive edge. Collectively, these strategies contribute to a moderately fragmented market structure, where innovation and operational efficiency are paramount. In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. This approach not only enhances responsiveness to market demands but also mitigates risks associated with global supply chain disruptions. The competitive structure of the Plasma Protease C1 Inhibitor Market is moderately fragmented, with several key players exerting influence through differentiated product offerings and strategic collaborations. In August 2025, CSL Behring (AU) announced a partnership with a leading biotechnology firm to co-develop a next-generation C1 inhibitor therapy. This collaboration is expected to accelerate the development timeline and enhance the therapeutic profile of their offerings, potentially positioning CSL Behring as a frontrunner in innovative treatment solutions. The strategic importance of this partnership lies in its potential to expand CSL Behring's market share and reinforce its commitment to addressing unmet medical needs in HAE treatment. In September 2025, Grifols (ES) unveiled a new manufacturing facility in the United States, aimed at increasing production capacity for its C1 inhibitor products. This investment reflects Grifols' strategy to enhance supply chain reliability and meet the growing demand for its therapies. The establishment of this facility is likely to improve operational efficiency and reduce time-to-market for new products, thereby strengthening Grifols' competitive position. In October 2025, Shire (GB) launched a [digital health](https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636) platform designed to support patients with HAE in managing their condition more effectively. This initiative underscores Shire's commitment to integrating technology into patient care, potentially improving treatment adherence and outcomes. The strategic significance of this move lies in its alignment with current trends towards digitalization in healthcare, which may enhance patient engagement and satisfaction. As of October 2025, the competitive trends in the Plasma Protease C1 Inhibitor Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative therapies, and robust supply chain management, reflecting a broader shift in the healthcare industry.

## Recent News & Developments

- **Q1 2024: Takeda Receives FDA Approval for TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe for Hereditary Angioedema** Takeda announced that the U.S. FDA approved a new prefilled syringe presentation of TAKHZYRO® (lanadelumab-flyo) for the prevention of hereditary angioedema attacks, expanding administration options for patients.
- **Q2 2024: CSL Behring Opens New Plasma Fractionation Facility in Marburg, Germany** CSL Behring inaugurated a new plasma fractionation facility in Marburg to increase production capacity for plasma-derived therapies, including C1-inhibitor products.
- **Q2 2024: Pharming Group Announces FDA Acceptance of sBLA for RUCONEST® for Expanded Indication** Pharming Group reported that the U.S. FDA accepted its supplemental Biologics License Application (sBLA) for RUCONEST® (C1 esterase inhibitor [recombinant]) to expand its indication for hereditary angioedema.
- **Q3 2024: Takeda Announces Partnership with BioLife Plasma Services to Expand Plasma Collection for C1-Inhibitor Therapies** Takeda entered a partnership with BioLife Plasma Services to increase plasma collection capacity, supporting the production of plasma-derived C1-inhibitor therapies.
- **Q3 2024: CSL Behring Receives European Commission Approval for Berinert® for Pediatric Use** CSL Behring received European Commission approval to extend the use of Berinert® (C1 esterase inhibitor) to pediatric patients with hereditary angioedema.
- **Q4 2024: Pharming Group Appoints New Chief Medical Officer** Pharming Group announced the appointment of a new Chief Medical Officer to oversee clinical development of its C1-inhibitor portfolio.
- **Q1 2025: Takeda Launches TAKHZYRO® Prefilled Syringe in Europe** Takeda launched the prefilled syringe formulation of TAKHZYRO® (lanadelumab-flyo) in several European countries, expanding access to hereditary angioedema patients.
- **Q1 2025: CSL Behring Announces Expansion of Kankakee Manufacturing Facility** CSL Behring announced a major expansion of its Kankakee, Illinois manufacturing facility to increase production of plasma-derived therapies, including C1-inhibitor products.
- **Q2 2025: Pharming Group Receives FDA Approval for Expanded RUCONEST® Indication** Pharming Group received FDA approval for an expanded indication of RUCONEST® (C1 esterase inhibitor [recombinant]) for the treatment of hereditary angioedema in additional patient populations.
- **Q2 2025: Takeda Announces New Plasma Collection Center Opening in Texas** Takeda opened a new plasma collection center in Texas to support the growing demand for plasma-derived C1-inhibitor therapies.

## Report Scope

| MARKET SIZE 2024 | 1.106(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.156(USD Billion) |
| MARKET SIZE 2035 | 1.79(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.47% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Shire (GB), CSL Behring (AU), Grifols (ES), Octapharma (CH), Takeda (JP), Baxter (US), LFB (FR), Sobi (SE) |
| Segments Covered | Product Formulation, Indication, Distribution Channel, End Users, Administration Route, Regional |
| Key Market Opportunities | Advancements in gene therapy may enhance treatment options in the Plasma Protease C1 Inhibitor Market. |
| Key Market Dynamics | Rising demand for Plasma Protease C1 Inhibitor therapies drives competitive innovation and regulatory scrutiny in the healthcare sector. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Plasma Protease C1 Inhibitor Market by 2035?**
A: The Plasma Protease C1 Inhibitor Market is projected to reach a valuation of 1.79 USD Billion by 2035.

**Q: What was the market valuation of the Plasma Protease C1 Inhibitor Market in 2024?**
A: In 2024, the market valuation of the Plasma Protease C1 Inhibitor Market was 1.106 USD Billion.

**Q: What is the expected CAGR for the Plasma Protease C1 Inhibitor Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Plasma Protease C1 Inhibitor Market during the forecast period 2025 - 2035 is 4.47%.

**Q: Which product formulation segment had the highest valuation in 2024?**
A: The Liquid Formulation segment had the highest valuation of 0.442 USD Billion in 2024.

**Q: What are the key indications driving the Plasma Protease C1 Inhibitor Market?**
A: The key indications include Hereditary Angioedema, which was valued at 0.66 USD Billion in 2024.

**Q: Which distribution channel is expected to show significant growth in the Plasma Protease C1 Inhibitor Market?**
A: The Online Pharmacies distribution channel is expected to show significant growth, with a valuation of 0.332 USD Billion in 2024.

**Q: What is the projected valuation for the Lyophilized Formulation segment by 2035?**
A: The Lyophilized Formulation segment is projected to reach a valuation of 0.528 USD Billion by 2035.

**Q: Which key players are leading the Plasma Protease C1 Inhibitor Market?**
A: Key players in the market include Shire, CSL Behring, Grifols, and Takeda.

**Q: What was the valuation of the Acquired Angioedema indication in 2024?**
A: The Acquired Angioedema indication was valued at 0.33 USD Billion in 2024.

**Q: What is the expected growth for the Homecare Settings end user segment by 2035?**
A: The Homecare Settings end user segment is expected to grow to a valuation of 0.31 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/plasma-protease-c1-inhibitor-market-32457*